| Systemic inflammatory response syndrome |
| Classification and external resources |
| ICD-9 |
995.90 |
In medicine, systemic inflammatory response syndrome (SIRS) is an inflammatory state affecting the whole body, frequently in response to infection, but not necessarily so. It is related to sepsis, a condition in which individuals both meet criteria for SIRS and have a known or highly suspected infection.
Classification
SIRS is one of several conditions related to systemic inflammation, organ dysfunction, and organ failure. It is a subset of cytokine storm, in which there is abnormal regulation of various cytokines.[citation needed] SIRS is also closely related to sepsis, in which patients satisfy criteria for SIRS and have a suspected or proven infection.[1][2][3]
Definition
SIRS was first described by Dr. William R. Nelson, of the University of Toronto, at the Nordic Micro Circulation meeting in Geilo, Norway in February of 1983. The intent of creating an encompassing definition was to bring together the multiple etiologies or post episode organ dysfunction (fibrin deposition,platelet aggregation, coagulopathies, leukocyte lysosomal release) into a family of negatively synergistic responses to injury and/or infection which can collectively lead to micro circulatory dysfunction. The implication of such a definition suggested that recognition of the activation of one of the above noted humoral pathways suggests that additional processes are also active. The aggregate of such path-physiology would lead to clinical conditions such as renal failure and/or pulmonary edema.
Criteria for SIRS were established in 1992 as part of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.[1] The conference concluded that the manifestations of SIRS include, but are not limited to:
SIRS can be diagnosed when two or more of these criteria are present.[2][3][4][5]
The International Pediatric Sepsis Consensus has proposed some changes to adapt these criteria to the pediatric population[6].
Fever and leukocytosis are features of the acute-phase reaction, while tachycardia is often the initial sign of hemodynamic compromise. Tachypnea may be related to the increased metabolic stress due to infection and inflammation, but may also be an ominous sign of inadequate perfusion resulting in the onset of anaerobic cellular metabolism.
In children, the SIRS criteria are modified in the following fashion:[7]
Note that SIRS criteria are very non-specific,[8] and must be interpreted carefully within the clinical context. These criteria exist primarily for the purpose of more objectively classifying critically-ill patients so that future clinical studies may be more rigorous and more easily reproducible.
As an alternative, when two or more of the systemic inflammatory response syndrome criteria are met without evidence of infection, patients may be diagnosed simply with "SIRS." Patients with SIRS and acute organ dysfunction may be termed "severe SIRS."
Complications
SIRS is frequently complicated by failure of one or more organs or organ systems.[1] The complications of SIRS include:
Causes
The causes of SIRS are broadly classified as infectious or noninfectious. As above, when SIRS is due to an infection, it is considered sepsis. Noninfectious causes of SIRS include trauma, burns, pancreatitis, ischemia, and hemorrhage.[1]
Other causes include:[citation needed]
Treatment
Generally, the treatment for SIRS is directed towards the underlying problem or inciting cause (i.e. adequate fluid replacement for hypovolemia, IVF/NPO for pancreatitis, epinephrine/steroids/benadryl for anaphylaxis).[1] Selenium, glutamine, and eicosapentaenoic acid have shown effectiveness in improving symptoms in clinical trials.[9] Other antioxidants such as vitamin E may be helpful as well.[10]
References
- ^ a b c d "American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis". Crit. Care Med. 20 (6): 864–74. 1992. PMID 1597042. http://www.chestjournal.org/content/101/6/1644.full.pdf.
- ^ a b Rippe, James M.; Irwin, Richard S.; Cerra, Frank B (1999). Irwin and Rippe's intensive care medicine. Philadelphia: Lippincott-Raven. ISBN 0-7817-1425-7.
- ^ a b Marino, Paul L. (1998). The ICU book. Baltimore: Williams & Wilkins. ISBN 0-683-05565-8.
- ^ Sharma S, Steven M. Septic Shock. eMedicine.com, URL: http://www.emedicine.com/MED/topic2101.htm Accessed on Nov 20, 2005.
- ^ Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J (March 2005). "Septic shock; current pathogenetic concepts from a clinical perspective". Medical Science Monitor : International Medical Journal of Experimental and Clinical Research 11 (3): RA76–85. PMID 15735579. http://www.medscimonit.com/fulltxt.php?ICID=15400.
- ^ Brahm Goldstein et al., International pediatric sepsis consensus, Pediatr Crit Care Med 2005 Vol. 6, No. 1
- ^ Goldstein B, Giroir B, Randolph A (2005). "International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics". Pediatr Crit Care Med 6 (1): 2–8. doi:10.1097/01.PCC.0000149131.72248.E6. PMID 15636651. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1529-7535&volume=6&issue=1&spage=2.
- ^ Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (Apr 2003). "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference". Crit Care Med 31 (4): 1250–1256. doi:10.1097/01.CCM.0000050454.01978.3B. http://www.ccmjournal.com/pt/re/ccm/abstract.00003246-200304000-00038.htm.
- ^ Berger MM, Chioléro RL (September 2007). "Antioxidant supplementation in sepsis and systemic inflammatory response syndrome". Critical Care Medicine 35 (9 Suppl): S584–90. doi:10.1097/01.CCM.0000279189.81529.C4. PMID 17713413. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/01.CCM.0000279189.81529.C4.
- ^ Bulger EM, Maier RV (February 2003). "An argument for Vitamin E supplementation in the management of systemic inflammatory response syndrome". Shock (Augusta, Ga.) 19 (2): 99–103. doi:10.1097/00024382-200302000-00001. PMID 12578114. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1073-2322&volume=19&issue=2&spage=99.